MX2013000079A - Tratamiento con l-metilfolato para desordenes psiquiatricos o neurologicos. - Google Patents
Tratamiento con l-metilfolato para desordenes psiquiatricos o neurologicos.Info
- Publication number
- MX2013000079A MX2013000079A MX2013000079A MX2013000079A MX2013000079A MX 2013000079 A MX2013000079 A MX 2013000079A MX 2013000079 A MX2013000079 A MX 2013000079A MX 2013000079 A MX2013000079 A MX 2013000079A MX 2013000079 A MX2013000079 A MX 2013000079A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- methylfolate
- subject
- psychiatric
- neurologic disorders
- Prior art date
Links
- 229940064128 l-methylfolate Drugs 0.000 title abstract 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 title abstract 3
- 235000007635 levomefolic acid Nutrition 0.000 title abstract 3
- 239000011578 levomefolic acid Substances 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 abstract 1
- 101150019913 MTHFR gene Proteins 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Aquí se proporcionan métodos para tratar desórdenes neuropsiquiátricos o mejorar los síntomas con ellos asociados administrando un alimento médico, tal como L-metilfolato, a un sujeto que tiene el desorden. El desorden neuropsiquiátrico puede ser un desorden del espectro del autismo o desorden de déficit de atención con o sin hiperactividad (ADD/ADHD). El L-metilfolato se puede administrar como auxiliar a otros agentes terapéuticos eficaces para tratar el desorden. El sujeto preferiblemente puede ser un niño y también puede tener un solo polimorfismo de nucleótido en el gen de MTHFR asociado con la expresión reducida de la enzima de MTHFR. También se proporciona un método para aumentar la síntesis de novo de neurotransmisores in vivo al transportar un compuesto donador de metilo a través de la barrera sangre-cerebro en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/803,643 US20120004238A1 (en) | 2010-07-01 | 2010-07-01 | L-methylfolate treatment for psychiatric or neurologic disorders |
| PCT/US2011/039700 WO2012003073A1 (en) | 2010-07-01 | 2011-06-09 | L-methylfolate treatment for psychiatric or neurologic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013000079A true MX2013000079A (es) | 2013-05-17 |
Family
ID=45400162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000079A MX2013000079A (es) | 2010-07-01 | 2011-06-09 | Tratamiento con l-metilfolato para desordenes psiquiatricos o neurologicos. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120004238A1 (es) |
| EP (1) | EP2588146A4 (es) |
| BR (1) | BR112012033695A2 (es) |
| CA (1) | CA2804016A1 (es) |
| MX (1) | MX2013000079A (es) |
| WO (1) | WO2012003073A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014201104A2 (en) * | 2013-06-11 | 2014-12-18 | Courtagen Life Sciences, Inc. | Methods and kits for treating and classifying individuals |
| US20150132273A1 (en) * | 2013-11-09 | 2015-05-14 | Rhett Sean Daniels | Nutritional Compositions and Methods for Treating Cognitive Impairment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037155A1 (en) * | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
| US6912492B1 (en) * | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| WO2006119589A2 (en) * | 2005-05-11 | 2006-11-16 | Ramaekers, Vincent | Prevention and therapy of cerebral folate deficiency |
-
2010
- 2010-07-01 US US12/803,643 patent/US20120004238A1/en not_active Abandoned
-
2011
- 2011-06-09 WO PCT/US2011/039700 patent/WO2012003073A1/en not_active Ceased
- 2011-06-09 BR BR112012033695A patent/BR112012033695A2/pt not_active IP Right Cessation
- 2011-06-09 EP EP11801314.3A patent/EP2588146A4/en not_active Withdrawn
- 2011-06-09 MX MX2013000079A patent/MX2013000079A/es active IP Right Grant
- 2011-06-09 CA CA2804016A patent/CA2804016A1/en not_active Abandoned
- 2011-09-20 US US13/237,373 patent/US8389535B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012003073A1 (en) | 2012-01-05 |
| US20120004238A1 (en) | 2012-01-05 |
| CA2804016A1 (en) | 2012-01-05 |
| EP2588146A4 (en) | 2014-05-28 |
| US20120010210A1 (en) | 2012-01-12 |
| EP2588146A1 (en) | 2013-05-08 |
| US8389535B2 (en) | 2013-03-05 |
| BR112012033695A2 (pt) | 2016-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2010004074A (es) | Combinacion 059. | |
| TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
| MX2013001272A (es) | Nuevo tratamiento del carcinoma de prostata. | |
| NZ706296A (en) | Glucosylceramide synthase inhibitors | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| MX2012003770A (es) | Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia. | |
| TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
| MA32784B1 (fr) | Composes aryles substitues par heterocycle comme inhibiteurs de hif | |
| PH12013502620A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| MX2015012520A (es) | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. | |
| FI3370760T3 (fi) | Plasminogeenivajauksen plasminogeenikorvaushoito | |
| EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
| TW200507847A (en) | Method for enhancing cognition using ziprasidone | |
| IL191796A0 (en) | Combination of zd6474 and pemetrexed | |
| PH12015501341A1 (en) | Chlorin derivative useful in photodynamic therapy and diagnosis | |
| MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
| GB0718878D0 (en) | Photodynamic Theraphy and diagnosis | |
| EA201491026A1 (ru) | Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 | |
| MX2013000079A (es) | Tratamiento con l-metilfolato para desordenes psiquiatricos o neurologicos. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| WO2012037008A3 (en) | Therapy for mll-rearranged leukemia | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |